The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes.
Our initial observation that type I collagen activates polymorphonuclear leukocytes (PMN) prompted the testing of the activating potential of type IV collagen. It was noted, however, that type IV collagen isolated from bovine lens capsule did not activate PMN but rather prevented their stimulation by N-formylmethionyl-leucyl-phenylalanine, phorbol myristate acetate, or type I collagen. This observation led to the present study, which demonstrates that the inhibitory effect of lens capsule type IV collagen resides in the noncollagenous (NC1) domain of the alpha 3 chain and specifically in the region comprising residues 185-203 of the NC1 domain of both the human and bovine molecules. Synthetic peptides from the same region of the NC1 domains of the alpha 1, alpha 2, alpha 4, and alpha 5 chains did not possess the inhibitory effect seen with the alpha 3 chain. The sequence S-N-S (residues 189-191) is unique to the peptide of the alpha 3 chain, and substitution of either serine with alanine abolishes the inhibition. Type IV collagen isolated from the mouse Engelbreth-Holm-Swarm (EHS) tumor, a molecule that lacks the alpha 3 chain, did not prevent PMN activation but instead stimulated the secretion of elastase and type IV collagenase. Incubation of PMN with intact lens capsule type IV collagen or a peptide comprising residues 185-203 of the alpha 3 (IV) chain resulted in a 3-fold increase of intracellular cAMP, whereas, Ca2+ levels remained unchanged. Incubating PMN with forskolin or with dibutyryl-cAMP resulted in the inhibition of O2- production and degranulation by PMN, thus mimicking the effects of type IV collagen and the alpha 3 (IV) 185-203 peptide. The data suggest that type IV collagen, through its alpha 3 chain, down-regulates PMN activation and thus decreases the potential for damage as these cells traverse the capillary wall. Our in vitro experiments suggest that the higher the content of the alpha 3 (IV) chain is in a basement membrane, the wider would be its capacity for self-protection.
Monboisse
J C
JC
Laboratory of Biochemistry, CNRS ERS 0017, University of Reims, France.
Garnotel
R
R
Bellon
G
G
Ohno
N
N
Perreau
C
C
Borel
J P
JP
Kefalides
N A
NA
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002417:Cattle; D005576:Colforsin / Q000494:pharmacology; D003094:Collagen / Q000138:chemical synthesis / Q000494:pharmacology*; D024141:Collagen Type IV; D017364:Collagenases / Q000096:biosynthesis; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D007908:Lens, Crystalline / Q000737:chemistry; D051379:Mice; D008969:Molecular Sequence Data; D018375:Neutrophil Activation / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010196:Pancreatic Elastase / Q000096:biosynthesis; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology*; D017433:Protein Structure, Secondary; D012513:Sarcoma, Experimental / Q000737:chemistry; D015398:Signal Transduction; D013045:Species Specificity; D013329:Structure-Activity Relationship; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D024141:Collagen Type IV; D010446:Peptide Fragments; D010566:Virulence Factors, Bordetella; C089942:collagen alpha3(IV) 185-203; D005576:Colforsin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D003994:Bucladesine; D003094:Collagen; D000242:Cyclic AMP; D010196:Pancreatic Elastase; D017364:Collagenases